🤝 This collaboration focuses on cloud-connected bioreactor technology.
🔧 They aim for joint hardware commercialization and technology development.
🌍 Cytiva will exclusively distribute the Stratyx 250 bioreactor globally.
💡 This effort promotes advanced, scalable, and connected biomanufacturing systems.
🚀 Both companies believe this partnership will accelerate the future of digital bioprocessing.
Introduction:
In a strategic move to enhance its bioprocessing capabilities, Cytiva has expanded its collaboration with Culture Biosciences, integrating both hardware commercialization and joint technology development in the field of cloud-connected bioreactor systems.
- Cytiva’s collaboration with Culture Biosciences is now broadened to include global commercialization of the Stratyx 250 bioreactor hardware and development of additional bioreactor formats.
- The relationship builds on an existing agreement to utilize Cytiva’s Xcellerex X-Platform technology in a scaled-down version for Culture’s Stratyx 250 system.
- Cytiva will act as the exclusive global distributor of the Stratyx 250 bioreactor platform, leveraging its extensive infrastructure for widespread access to advanced bioprocessing technologies.
- The partnership aims to accelerate the development of next-generation, small-scale bioprocessing solutions to enhance the efficiency of biomanufacturing systems.
- Future product expansions will feature consumables that enable a seamless transition from small-scale bioreactor systems of 250 mL to larger systems up to 2,000 liters.
Conclusion:
This expanded collaboration between Cytiva and Culture Biosciences signifies a substantial advancement in the drive towards digital and automated bioprocessing solutions. By combining forces, the two companies are poised to facilitate smarter and more scalable biomanufacturing systems, which will likely lead to innovations in the biotechnology space and improve the accessibility of bioprocess technologies worldwide.
